Enlivex Therapeutics ENLV Stock
Enlivex Therapeutics Price Chart
Enlivex Therapeutics ENLV Financial and Trading Overview
| Enlivex Therapeutics stock price | 1 USD |
| Previous Close | 2.83 USD |
| Open | 2.78 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1000 |
| Day's Range | 2.75 - 2.97 USD |
| 52 Week Range | 2.23 - 6.15 USD |
| Volume | 39.74K USD |
| Avg. Volume | 36.66K USD |
| Market Cap | 52.17M USD |
| Beta (5Y Monthly) | 0.60495 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ENLV Valuation Measures
| Enterprise Value | 6.37M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.0510948 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.9105638 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.255 |
Trading Information
Enlivex Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.60495 |
| 52-Week Change | -29.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.15 USD |
| 52 Week Low | 2.23 USD |
| 50-Day Moving Average | 2.78 USD |
| 200-Day Moving Average | 3.88 USD |
ENLV Share Statistics
| Avg. Volume (3 month) | 36.66K USD |
| Avg. Daily Volume (10-Days) | 36.13K USD |
| Shares Outstanding | 18.57M |
| Float | 14.8M |
| Short Ratio | 6.73 |
| % Held by Insiders | 11.82% |
| % Held by Institutions | 9.75% |
| Shares Short | 121.19K |
| Short % of Float | 0.69% |
| Short % of Shares Outstanding | 0.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:8 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.80% |
| Return on Equity (ttm) | -43.78% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -25020000 USD |
| Net Income Avi to Common (ttm) | -31060000 USD |
| Diluted EPS (ttm) | -1.84 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 50.24M USD |
| Total Cash Per Share (mrq) | 2.73 USD |
| Total Debt (mrq) | 4.85M USD |
| Total Debt/Equity (mrq) | 8.53 USD |
| Current Ratio (mrq) | 7.92 |
| Book Value Per Share (mrq) | 3.086 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -23953000 USD |
| Levered Free Cash Flow (ttm) | -18677124 USD |
Profile of Enlivex Therapeutics
| Country | United States |
| State | N/A |
| City | Ness Ziona |
| Address | 14 Einstein Street |
| ZIP | 7403618 |
| Phone | 972 8 662 3301 |
| Website | https://www.enlivex.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Q&A For Enlivex Therapeutics Stock
What is a current ENLV stock price?
Enlivex Therapeutics ENLV stock price today per share is 1 USD.
How to purchase Enlivex Therapeutics stock?
You can buy ENLV shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Enlivex Therapeutics?
The stock symbol or ticker of Enlivex Therapeutics is ENLV.
Which industry does the Enlivex Therapeutics company belong to?
The Enlivex Therapeutics industry is Biotechnology.
How many shares does Enlivex Therapeutics have in circulation?
The max supply of Enlivex Therapeutics shares is 23.85M.
What is Enlivex Therapeutics Price to Earnings Ratio (PE Ratio)?
Enlivex Therapeutics PE Ratio is now.
What was Enlivex Therapeutics earnings per share over the trailing 12 months (TTM)?
Enlivex Therapeutics EPS is -0.73 USD over the trailing 12 months.
Which sector does the Enlivex Therapeutics company belong to?
The Enlivex Therapeutics sector is Healthcare.
Enlivex Therapeutics ENLV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19199.16 USD — |
+2.47
|
8.02B USD — | 18961.69 USD — | 19210.95 USD — | — - | 8.02B USD — |
| NASDAQ Capital Market Composite RCMP | 114.46 USD — |
+1.8
|
— — | 113.76 USD — | 115.05 USD — | — - | — — |
| Nasdaq Health Care IXHC | 946.2 USD — |
+1.52
|
— — | 941.18 USD — | 951.02 USD — | — - | — — |
- {{ link.label }} {{link}}